Compare Sana Biotechnology Inc (SANA) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Sana Biotechnology Inc trades at $2.81 (market cap $836.71M), while iShares 0 3 Month Treasury Bond ETF trades at $100.52 (market cap $114.40B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 136.7× Sana Biotechnology Inc's market cap, and iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and iShares 0 3 Month Treasury Bond ETF for 50 Days on average.
| SANA | SGOV | |
|---|---|---|
Market Cap | $836.71M | $114.40B |
Volume | 4,507,444 | 18,879,081 |
Sector | Health | Fixed Income |
52-Week High | $5.92 | $100.72 |
52-Week Low | $2.68 | $100.28 |
Typical Hold Time | 23 Days | 50 Days |
Enterprise Value | $749.96M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
SGOV trades at $100.515 with minimal daily movement (+0.05%). The technical outlook is bearish with moving averages signaling selling pressure, though oscillators are neutral. Recent dividends of $0.30-0.31 per share were declared for H2-2026. The ETF focuses on short-term Treasury bonds, with institutional activity showing Envestnet reduced its position by 13.2% in Q2 2026.
The outlook remains cautious amid rising Treasury yields and bond market volatility. Higher interest rates could pressure short-term bond ETFs like SGOV, though they offer relative safety. Key risks include Fed policy shifts and inflation trends. Investors should weigh yield advantages against duration risk in the current rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
